Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice

A. D. Sette, C. Oseroff, J. Sidney, J. Alexander, R. W. Chesnut, K. Kakimi, L. G. Guidotti, F. V. Chisari

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The sequence of the hepatitis B virus (HBV) major envelope (Env) protein (ayw subtype) was scanned for the presence of H-2d,b motifs. Following binding and immunogenicity testing, two new H-2d-restricted epitopes (Env.362 and Env.364) were identified. These epitopes induced CTLs capable of recognizing naturally processed HBV-Env, but were apparently generated with lower efficiency than the previously defined dominant Env.28 epitope. Next, HBV-transgenic mice that express all of the HBV proteins and produce fully infectious particles were immunized with a mixture of lipopeptides encompassing the Env.28, Env.362, and Env.364 epitopes. Significant CTL responses were obtained, but they had no effect on viral replication in the liver, nor did they induce an inflammatory liver disease. However, in adoptive transfer experiments, CTL lines generated from the HBV-transgenic mice following immunization were able to inhibit viral replication in vivo without causing hepatitis. This is in contrast to CTL lines derived from nontransgenic mice that displayed both antiviral and cytopathic effects, presumably because they displayed higher avidity for the viral epitopes than the transgenic CTLs. These results suggest that T cell tolerance to HBV can be broken with appropriate immunization but the magnitude and characteristics of the resultant T cell response are significantly different from the response in HBV-naive individuals since their antiviral potential is stronger than their cytotoxic potential. This has obvious implications for immunotherapy of chronic HBV infection.

Original languageEnglish
Pages (from-to)1389-1397
Number of pages9
JournalJournal of Immunology
Volume166
Issue number2
Publication statusPublished - Jan 15 2001

Fingerprint

Hepatitis B Surface Antigens
Hepatitis B virus
Transgenic Mice
T-Lymphocytes
Epitopes
Antiviral Agents
Immunization
Viral Envelope Proteins
Lipopeptides
Adoptive Transfer
Chronic Hepatitis B
Virus Diseases
Immunotherapy
Hepatitis
Liver Diseases
Liver

ASJC Scopus subject areas

  • Immunology

Cite this

Sette, A. D., Oseroff, C., Sidney, J., Alexander, J., Chesnut, R. W., Kakimi, K., ... Chisari, F. V. (2001). Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. Journal of Immunology, 166(2), 1389-1397.

Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. / Sette, A. D.; Oseroff, C.; Sidney, J.; Alexander, J.; Chesnut, R. W.; Kakimi, K.; Guidotti, L. G.; Chisari, F. V.

In: Journal of Immunology, Vol. 166, No. 2, 15.01.2001, p. 1389-1397.

Research output: Contribution to journalArticle

Sette, AD, Oseroff, C, Sidney, J, Alexander, J, Chesnut, RW, Kakimi, K, Guidotti, LG & Chisari, FV 2001, 'Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice', Journal of Immunology, vol. 166, no. 2, pp. 1389-1397.
Sette AD, Oseroff C, Sidney J, Alexander J, Chesnut RW, Kakimi K et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. Journal of Immunology. 2001 Jan 15;166(2):1389-1397.
Sette, A. D. ; Oseroff, C. ; Sidney, J. ; Alexander, J. ; Chesnut, R. W. ; Kakimi, K. ; Guidotti, L. G. ; Chisari, F. V. / Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. In: Journal of Immunology. 2001 ; Vol. 166, No. 2. pp. 1389-1397.
@article{df5247e5803b442385991ee1f457d010,
title = "Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice",
abstract = "The sequence of the hepatitis B virus (HBV) major envelope (Env) protein (ayw subtype) was scanned for the presence of H-2d,b motifs. Following binding and immunogenicity testing, two new H-2d-restricted epitopes (Env.362 and Env.364) were identified. These epitopes induced CTLs capable of recognizing naturally processed HBV-Env, but were apparently generated with lower efficiency than the previously defined dominant Env.28 epitope. Next, HBV-transgenic mice that express all of the HBV proteins and produce fully infectious particles were immunized with a mixture of lipopeptides encompassing the Env.28, Env.362, and Env.364 epitopes. Significant CTL responses were obtained, but they had no effect on viral replication in the liver, nor did they induce an inflammatory liver disease. However, in adoptive transfer experiments, CTL lines generated from the HBV-transgenic mice following immunization were able to inhibit viral replication in vivo without causing hepatitis. This is in contrast to CTL lines derived from nontransgenic mice that displayed both antiviral and cytopathic effects, presumably because they displayed higher avidity for the viral epitopes than the transgenic CTLs. These results suggest that T cell tolerance to HBV can be broken with appropriate immunization but the magnitude and characteristics of the resultant T cell response are significantly different from the response in HBV-naive individuals since their antiviral potential is stronger than their cytotoxic potential. This has obvious implications for immunotherapy of chronic HBV infection.",
author = "Sette, {A. D.} and C. Oseroff and J. Sidney and J. Alexander and Chesnut, {R. W.} and K. Kakimi and Guidotti, {L. G.} and Chisari, {F. V.}",
year = "2001",
month = "1",
day = "15",
language = "English",
volume = "166",
pages = "1389--1397",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice

AU - Sette, A. D.

AU - Oseroff, C.

AU - Sidney, J.

AU - Alexander, J.

AU - Chesnut, R. W.

AU - Kakimi, K.

AU - Guidotti, L. G.

AU - Chisari, F. V.

PY - 2001/1/15

Y1 - 2001/1/15

N2 - The sequence of the hepatitis B virus (HBV) major envelope (Env) protein (ayw subtype) was scanned for the presence of H-2d,b motifs. Following binding and immunogenicity testing, two new H-2d-restricted epitopes (Env.362 and Env.364) were identified. These epitopes induced CTLs capable of recognizing naturally processed HBV-Env, but were apparently generated with lower efficiency than the previously defined dominant Env.28 epitope. Next, HBV-transgenic mice that express all of the HBV proteins and produce fully infectious particles were immunized with a mixture of lipopeptides encompassing the Env.28, Env.362, and Env.364 epitopes. Significant CTL responses were obtained, but they had no effect on viral replication in the liver, nor did they induce an inflammatory liver disease. However, in adoptive transfer experiments, CTL lines generated from the HBV-transgenic mice following immunization were able to inhibit viral replication in vivo without causing hepatitis. This is in contrast to CTL lines derived from nontransgenic mice that displayed both antiviral and cytopathic effects, presumably because they displayed higher avidity for the viral epitopes than the transgenic CTLs. These results suggest that T cell tolerance to HBV can be broken with appropriate immunization but the magnitude and characteristics of the resultant T cell response are significantly different from the response in HBV-naive individuals since their antiviral potential is stronger than their cytotoxic potential. This has obvious implications for immunotherapy of chronic HBV infection.

AB - The sequence of the hepatitis B virus (HBV) major envelope (Env) protein (ayw subtype) was scanned for the presence of H-2d,b motifs. Following binding and immunogenicity testing, two new H-2d-restricted epitopes (Env.362 and Env.364) were identified. These epitopes induced CTLs capable of recognizing naturally processed HBV-Env, but were apparently generated with lower efficiency than the previously defined dominant Env.28 epitope. Next, HBV-transgenic mice that express all of the HBV proteins and produce fully infectious particles were immunized with a mixture of lipopeptides encompassing the Env.28, Env.362, and Env.364 epitopes. Significant CTL responses were obtained, but they had no effect on viral replication in the liver, nor did they induce an inflammatory liver disease. However, in adoptive transfer experiments, CTL lines generated from the HBV-transgenic mice following immunization were able to inhibit viral replication in vivo without causing hepatitis. This is in contrast to CTL lines derived from nontransgenic mice that displayed both antiviral and cytopathic effects, presumably because they displayed higher avidity for the viral epitopes than the transgenic CTLs. These results suggest that T cell tolerance to HBV can be broken with appropriate immunization but the magnitude and characteristics of the resultant T cell response are significantly different from the response in HBV-naive individuals since their antiviral potential is stronger than their cytotoxic potential. This has obvious implications for immunotherapy of chronic HBV infection.

UR - http://www.scopus.com/inward/record.url?scp=0035863924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035863924&partnerID=8YFLogxK

M3 - Article

VL - 166

SP - 1389

EP - 1397

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -